Abstract
BackgroundThe safety and efficacy of apremilast (APR), including improvements in physical disability, were compared with placebo in the PALACE 1 study of patients who had active psoriatic arthritis despite prior...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
